TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8484166

Group type: EXPERIMENTAL
Intervention: Mobilisation with the aircast splint (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Unna's paste dressing for two weeks with subsequent tape dressings and immediate mobilisation (Group C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Immobilisation in a plaster cast for three weeks followed by mobilisation with the aircast splint (Group A)
Number of subjects: 120
Study: 3680816

Group type: EXPERIMENTAL
Intervention: Uniphyl (once-a-day theophylline formulation) after breakfast
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Uniphyl (once-a-day theophylline formulation) after overnight fast
Number of subjects: 8

Group type: COMPARATOR
Intervention: Reference theophylline solution
Number of subjects: 8
Study: 29961666

Group type: EXPERIMENTAL
Intervention: Nursing intervention trial
Number of subjects: 0
Study: 27478057

Group type: EXPERIMENTAL
Intervention: Collaborative care tools and care facilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based therapy tools and increased team meetings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training for primary care providers
Number of subjects: 0
Study: 25338241

Group type: EXPERIMENTAL
Intervention: Protected collection technique
Number of subjects: 54

Group type: COMPARATOR
Intervention: Traditional collection technique
Number of subjects: 54
Study: 23454601

Group type: EXPERIMENTAL
Intervention: WebChoice intervention
Number of subjects: 325
Study: 20032169

Group type: EXPERIMENTAL
Intervention: PACCTS intervention (telephone-based support)
Number of subjects: 9
Study: 19050530

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous dosing of cefazolin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intraoperative dosing by irrigation of cefazolin
Number of subjects: 24
Study: 16631656

Group type: EXPERIMENTAL
Intervention: On-pump, EC with closed SMA circuit and no pump suckers (n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: On-pump, EC with open SMA circuit and pump suckers (n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Off-pump (beating heart) and heparin 3 mg/kg (n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Off-pump (beating heart) and heparin 1 mg/kg (n = 20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: On-pump groups (1 and 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 14557556

Group type: EXPERIMENTAL
Intervention: GABA+
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GLX
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NAAt
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GLX/NAAt ratio
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GLX/Ins ratio
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ins
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cr
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cho
Number of subjects: 21
Study: 11865269

Group type: EXPERIMENTAL
Intervention: Dobutamine (10 microg/kg/min, increased to 20 microg/kg/min if needed)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dopamine (10 microg/kg/min, increased to 20 microg/kg/min if needed)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dobutamine (at 24 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both dobutamine and dopamine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dobutamine and dopamine
Number of subjects: 42
Study: 9696209

Group type: EXPERIMENTAL
Intervention: Serum IgG antibodies to C. trachomatis in poor responders (44.7%)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Patients undergoing IVF (36%)
Number of subjects: 323
Study: 10150262

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (1.0 to 2.0 g ampicillin plus 0.5 to 1.0 g sulbactam every 6 hours)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cefoxitin (1.0 to 2.0 g every 6 hours)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Ampicillin/sulbactam
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 76
Study: 3190058

Group type: EXPERIMENTAL
Intervention: Zidovudine (2 g/d for 2 weeks, and 1 g/d for 6 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 10
Study: 31099167

Group type: EXPERIMENTAL
Intervention: Spectator group watching professional baseball games at the ballpark for 2 months (median 6 days, interquartile range 4-10 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waiting-list group maintaining daily routines
Number of subjects: 58
Study: 28710996

Group type: EXPERIMENTAL
Intervention: CE‐Marked Alere™ HIV Combo
Number of subjects: 5029

Group type: EXPERIMENTAL
Intervention: Alere Determine™ HIV‐1/2 Ag/Ab Combo
Number of subjects: 5029

Group type: EXPERIMENTAL
Intervention: GS HIV Combo Ag/Ab EIA
Number of subjects: 5029

Group type: COMPARATOR
Intervention: Multispot®
Number of subjects: 5029

Group type: COMPARATOR
Intervention: Western Blot (WB)
Number of subjects: 5029

Group type: COMPARATOR
Intervention: Geenius™ (Bio‐Rad)
Number of subjects: 5029
Study: 26582611

Group type: EXPERIMENTAL
Intervention: Head elevated (10° angle of inclination)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Head in neutral position (face parallel to the operating room table)
Number of subjects: 52
Study: 23752604

Group type: EXPERIMENTAL
Intervention: G-CSF therapy and CVC-related sepsis
Number of subjects: 59

Group type: COMPARATOR
Intervention: Pre-treatment levels
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: IL-10 levels in sepsis
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: IL-12 levels in sepsis
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Serial determinations of serum IL-10 and IL-12
Number of subjects: 59
Study: 21765206

Group type: EXPERIMENTAL
Intervention: Alprazolam (low and high doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19836089

Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS)
Number of subjects: 47
Study: 16648504

Group type: EXPERIMENTAL
Intervention: Oral topotecan 1.7 mg/m2/d x 5 with IV cisplatin 60 mg/m2 on day 5 (TC)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Intravenous etoposide 100 mg/m2/d x 3 with IV cisplatin 80 mg/m2 on day 1 (PE)
Number of subjects: 784
Study: 15494083

Group type: EXPERIMENTAL
Intervention: Automatic fall detection units
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Automatic fall detection units (used occasionally by 62% of subgroup)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no fall detection units)
Number of subjects: 55
Study: 11284748

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% and Timolol 0.5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9165412

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (hetastarch)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Crystalloid
Number of subjects: 30
Study: 7963140

Group type: EXPERIMENTAL
Intervention: 6400 micrograms folate plus 20 micrograms cobalamin
Number of subjects: 26

Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 26
Study: 3622543

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30848868

Group type: EXPERIMENTAL
Intervention: Twice daily short-message-based re-education (SMRE)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group (oral and written instructions)
Number of subjects: 310
Study: 27003153

Group type: EXPERIMENTAL
Intervention: X-ray evaluation for abdominal aortic calcification (AAC)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: AAC score ≥4
Number of subjects: 280
Study: 24784143

Group type: COMPARATOR
Intervention: LOW-C (low-percent-energy-from-drinking-containers)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: HIGH-C (high-percent-energy-from-drinking-containers)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Both groups (LOW-C and HIGH-C)
Number of subjects: 299
Study: 23497243

Group type: EXPERIMENTAL
Intervention: Summative assessments
Number of subjects: 534

Group type: COMPARATOR
Intervention: Lectures and peer teaching
Number of subjects: 534

Group type: COMPARATOR
Intervention: Formative assessments
Number of subjects: 534
Study: 21823423

Group type: EXPERIMENTAL
Intervention: Bushen Tiaojing Recipe and GnRHa/FSH/hCG
Number of subjects: 58

Group type: COMPARATOR
Intervention: GnRHa/FSH/hCG
Number of subjects: 58
Study: 19325469

Group type: EXPERIMENTAL
Intervention: Stress doses of hydrocortisone
Number of subjects: 36
Study: 16198059

Group type: EXPERIMENTAL
Intervention: quetiapine (400 mg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: risperidone (4 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: fluphenazine (12.5 mg/day)
Number of subjects: 27
Study: 15349006

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg for 8 weeks
Number of subjects: 222
Study: 11286468

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day, n = 84)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Toremifene (40 mg/day, n = 83)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Toremifene (40 mg/day)
Number of subjects: 167
Study: 9200375

Group type: EXPERIMENTAL
Intervention: Newborns (mean leptin concentration 10.57 ng/mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Children in Tanner stages 1 and 2 (mean leptin concentration 3.04 ng/mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mothers (mean leptin concentration 28.8 ng/mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Placental tissue
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Human trophoblastic placental cell lines (JAR and JEG‐3)
Number of subjects: 100
Study: 7905185

Group type: EXPERIMENTAL
Intervention: 150 mg Roxatidine acetate once daily, late in the evening (between 10.00 p.m. and 11.00 p.m.)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: 150 mg Roxatidine acetate once daily, early in the evening (between 6.00 p.m. and 7.00 p.m.)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Both groups (bedtime and early evening administration)
Number of subjects: 730
Study: 2952436

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bendrofluazide (2.5 mg daily)
Number of subjects: 25
Study: 31840640

Group type: EXPERIMENTAL
Intervention: Visual Aid (VA) counseling
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Teach-Back (TB) counseling
Number of subjects: 85

Group type: COMPARATOR
Intervention: Caregivers not familiar with toothpaste guidelines
Number of subjects: 85
Study: 26577062

Group type: EXPERIMENTAL
Intervention: Mirtazapine (single dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 30
Study: 25904650

Group type: EXPERIMENTAL
Intervention: PEMI + CPT
Number of subjects: 16

Group type: COMPARATOR
Intervention: PEMI
Number of subjects: 16

Group type: COMPARATOR
Intervention: IHG
Number of subjects: 16
Study: 23864536

Group type: EXPERIMENTAL
Intervention: Habit formation intervention for serving fruit/vegetables, healthy snacks, and nonsweetened drinks (n = 58)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No-treatment control (n = 68)
Number of subjects: 126
Study: 19897276

Group type: EXPERIMENTAL
Intervention: Choline supplement (1500 mg twice daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard pharmacotherapy
Number of subjects: 76
Study: 17490465

Group type: EXPERIMENTAL
Intervention: Heavy resistance training (80% of 1 RM) for 12 weeks
Number of subjects: 11
Study: 15093917

Group type: COMPARATOR
Intervention: Whole bladder conformal radiotherapy (WBRT, 52.5 Gy in 20 fractions, n = 60)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Partial bladder conformal RT (PBRT4, 57.5 Gy in 20 fractions, n = 44)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Partial bladder conformal RT (PBRT3, 55 Gy in 16 fractions, n = 45)
Number of subjects: 149
Study: 11507807

Group type: EXPERIMENTAL
Intervention: Composite inlays (Tetric, Blend‐a‐Lux, Pertac)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ceramic inlays (Empress)
Number of subjects: 71
Study: 9571512

Group type: EXPERIMENTAL
Intervention: VDT workers with asthenopia
Number of subjects: 407

Group type: COMPARATOR
Intervention: VDT workers without asthenopia
Number of subjects: 407

Group type: COMPARATOR
Intervention: Non-VDT workers
Number of subjects: 407
Study: 8311367

Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 0
Study: 2977272

Group type: EXPERIMENTAL
Intervention: Zoladex (LH-RH analogue), administered every 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study: 31446387

Group type: EXPERIMENTAL
Intervention: Experience information denoted by neutral words in the HA group
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Experience information denoted by positive words in the HA group
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Experience information denoted by negative words in the HA group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Experience information denoted by neutral words in the LA group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Experience information denoted by positive words in the LA group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Experience information denoted by negative words in the LA group
Number of subjects: 2
Study: 29346524

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (exercise training, hyperproteic nutritional shakes, memory training, medication review)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 352
Study: 26938682

Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) group, n=56
Number of subjects: 115

Group type: COMPARATOR
Intervention: Cyclosporine (CyA) group, n=59
Number of subjects: 115
Study: 25267163

Group type: EXPERIMENTAL
Intervention: DFET (double frozen embryo transfer)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: eSFET (elective single frozen embryo transfers)
Number of subjects: 306
Study: 22450070

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (EVH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open vein harvest (OVH)
Number of subjects: 0
Study: 20093899

Group type: EXPERIMENTAL
Intervention: Psycho-behavioral intervention (n=521)
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Usual care (n=523)
Number of subjects: 1044
Study: 17909844

Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hypoxia (sildenafil)
Number of subjects: 14
Study: 15925474

Group type: EXPERIMENTAL
Intervention: Uncemented custom made Unique stem
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cemented Elite Plus stem
Number of subjects: 37
Study: 12358242

Group type: EXPERIMENTAL
Intervention: Nasojejunal feeding (group EN), n = 26
Number of subjects: 50

Group type: COMPARATOR
Intervention: Parenteral feeding (group TPN), n = 27
Number of subjects: 50
Study: 10471520

Group type: EXPERIMENTAL
Intervention: c-erbB-2 gene amplification detected by PCR
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: c-erbB-2 expression analyzed by IHC
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Concordance of PCR and IHC techniques
Number of subjects: 81
Study: 8566259

Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (tibolone and placebo)
Number of subjects: 31
Study: 1929258

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 23
Study: 7059489

Group type: COMPARATOR
Intervention: Sherry (40 ml) after placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Chlorpropamide before sherry
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo before sherry
Number of subjects: 35
Study: 31157682

Group type: EXPERIMENTAL
Intervention: ROTEM (Rotational thromboelastometry)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ROTEM
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of ROTEM values with protein C or antithrombin
Number of subjects: 23
Study: 28843866

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided bilateral rectus sheath block (BRSB) with 10ml of 0.5% ropivacaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Surgical bilateral rectus sheath block (BRSB) with 10ml of 0.5% ropivacaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group received 10ml of normal saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: US-guidance BRSB
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Surgical BRSB
Number of subjects: 75
Study: 25715353

Group type: EXPERIMENTAL
Intervention: Zinc gluconate and high-dose prednisolone (tapering for 2 weeks)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Zinc gluconate only
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prednisolone only
Number of subjects: 39

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 39
Study: 22982689

Group type: EXPERIMENTAL
Intervention: Pharmacist-initiated reduction of ADS score after multidisciplinary drug reviews
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study: 21726463

Group type: EXPERIMENTAL
Intervention: Rehabilitation program (4-week program designed, monitored, and progressed by a physiotherapist)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Advice (verbal and written advice about exercise)
Number of subjects: 342
Study: 19554274

Group type: EXPERIMENTAL
Intervention: Combination of connective tissue massage, Mc Mennell joint manipulation, and home exercise programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home exercise programme
Number of subjects: 40
Study: 17395338

Group type: EXPERIMENTAL
Intervention: LAIV-T
Number of subjects: 6403

Group type: COMPARATOR
Intervention: TIV
Number of subjects: 6403
Study: 15054673

Group type: EXPERIMENTAL
Intervention: 4 mg IV ondansetron before anesthetic induction plus 4 mg IV immediately before extubation (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4 mg IV ondansetron before anesthetic induction (control group)
Number of subjects: 60
Study: 11642472

Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg and 20 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9443427

Group type: EXPERIMENTAL
Intervention: Intravenous conjugated estrogens (1.25 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7872224

Group type: EXPERIMENTAL
Intervention: 3.9 g konjac glucomannan daily for 4 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 2124386

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 71
Study: 7425269

Group type: EXPERIMENTAL
Intervention: Atropine i.v.
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Droperidol-fentanyl-atropine
Number of subjects: 241

Group type: COMPARATOR
Intervention: Pentazocine-atropine
Number of subjects: 241
Study: 31312016

Group type: EXPERIMENTAL
Intervention: Advanced weight-bearing mat exercises (AWMEs)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Advanced weight-bearing mat exercises (AWMEs) with functional electrical stimulation (FES)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no exercise and no FES)
Number of subjects: 16
Study: 31051151

Group type: EXPERIMENTAL
Intervention: Clinical Congestion Index ≥3 at baseline
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Clinical Congestion Index of 0, 1-2, and ≥3 at inclusion
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Clinical Congestion Index
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Successful decongestion
Number of subjects: 588
Study: 28673312

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes (11.6 to 0.2 mg/cigarette)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual nicotine content (UNC) cigarettes (11.6 mg/cigarette)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Both RNC and UNC cigarettes
Number of subjects: 280
Study: 25190739

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Moderate-intensity aerobic continuous training (MI‐ACT)
Number of subjects: 19
Study: 23837807

Group type: EXPERIMENTAL
Intervention: Computer tool (CARE) and rapid HIV testing before a standard visit
Number of subjects: 517

Group type: COMPARATOR
Intervention: Standard visit with chart access
Number of subjects: 517
Study: 20535796

Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Self‐efficacy for pain control
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Self‐efficacy for physical function
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Self‐efficacy domains
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Total model
Number of subjects: 263
Study: 18266532

Group type: EXPERIMENTAL
Intervention: Structural ecosystems therapy (SET)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Family process‐only condition (FAM)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Community services control (CS)
Number of subjects: 190
Study: 16780497

Group type: EXPERIMENTAL
Intervention: Topical photodynamic therapy (PDT) weekly for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical paromomycin twice-daily for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14639941

Group type: EXPERIMENTAL
Intervention: Optimal Case Management (OCM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine Case Management (RCM)
Number of subjects: 100